BRISBANE, California | January 7, 2026 — CareDx and 10x Genomics have announced the launch of ImmuneScape™, a multiomics research program designed to decode the cellular and molecular mechanisms of transplant rejection and drug response. The collaboration brings together precision diagnostics expertise and advanced single-cell and spatial biology platforms to generate high-resolution immune maps that could shape the next generation of clinical transplant diagnostics.
Science Significance
At its core, ImmuneScape™ represents a major scientific advance in transplant immunology, targeting complex processes such as antibody-mediated rejection (AMR) and microvascular inflammation (MVI) that remain incompletely understood. By leveraging single-cell transcriptomics and spatial profiling technologies, the program aims to capture immune activity at cellular resolution and spatial context, an approach previously inaccessible at scale. The initiative will analyze gene expression signatures, immune cell populations, and tissue-level architecture, offering unprecedented insights into disease origin, progression, and therapeutic response variability. These data are expected to close long-standing gaps in understanding why transplant outcomes differ among patients receiving similar therapies.
Regulatory Significance
While ImmuneScape™ is positioned as a research initiative, its outcomes are clearly aligned with future regulatory-facing diagnostic development. The generation of high-quality, reproducible multiomics datasets supports the foundational evidence needed for regulated clinical diagnostics and companion tools. For regulators and quality-focused stakeholders, the program highlights the increasing role of data integrity, consistency, and analytical validity in next-generation diagnostics. As such platforms mature, they are likely to influence regulatory science frameworks, particularly in how omics-driven biomarkers are evaluated for clinical use under evolving GxP expectations.
Business Significance
Advertisement
From a business perspective, the collaboration strengthens CareDx’s diagnostic pipeline strategy while reinforcing 10x Genomics’ leadership in enabling translational research at scale. ImmuneScape™ builds upon CareDx’s expanding portfolio of genomics-based transplant solutions, positioning the company to develop clinically differentiated, high-value diagnostic products. For 10x Genomics, the partnership showcases real-world application of its Xenium spatial and Chromium Flex platforms in large-cohort, clinically relevant research. Together, the companies are creating a long-term innovation engine that could translate scientific discovery into commercial diagnostic offerings.
Patients’ Significance
For transplant patients, the implications are profound. Transplant rejection remains a leading cause of graft failure, often detected late and treated with trial-and-error approaches. By improving understanding of immune pathways and rejection subtypes, ImmuneScape™ has the potential to enable earlier detection, more precise treatment selection, and better outcome prediction. Over time, insights from this research could lead to personalized transplant care, reducing unnecessary immunosuppression, minimizing adverse effects, and ultimately improving graft survival and quality of life for patients.
Policy Significance
At a policy level, ImmuneScape™ underscores the growing importance of precision medicine, genomics, and data-driven healthcare innovation. As healthcare systems and policymakers push toward value-based care and personalized treatment models, programs like this provide the scientific foundation needed to justify policy shifts. The initiative also supports broader policy goals related to advanced diagnostics adoption, translational research funding, and innovation-friendly regulatory pathways, particularly in high-burden therapeutic areas such as organ transplantation.
The launch of ImmuneScape™ marks a strategic convergence of multiomics science, clinical insight, and diagnostic innovation. By decoding the immune biology of transplant rejection at unprecedented resolution, CareDx and 10x Genomics are laying the groundwork for future-ready diagnostics that align scientific discovery with clinical, regulatory, and patient needs. As precision medicine continues to reshape healthcare, ImmuneScape™ stands out as a forward-looking model for how advanced research platforms can translate into real-world impact across the transplant ecosystem.
Source: CareDx, Inc press release
